Search
Powered By HealthLine
Special Offers
TV Specials
 Learn about an Effective Alzheimer's Medication
 Bipolar Education Health Center
 Osteoarthritis of the Knee Solution Center
 Heartburn Education Center
 Breast Cancer Health Center
 Crohn's Disease Health Center
 Schizophrenia Education Center
Top Features
 Depression
 Schizophrenia
 Breast Cancer
 Bipolar
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Hepatitis E Vaccine Called Highly Effective

The virus is typically found in undeveloped countries with poor sanitation

By Serena Gordon
HealthDay Reporter


Related Encyclopedia
 border=
Abscess
Actinomycosis
Acute Myeloid Leukemia (Adult)
AIDS and HIV Infection
More...

Related Healthscout Videos
 border=
Fighting HIV
Fighting a Killer Staph Infection
Antibiotic Mist for Sinus Problems
Best HIV Combo
More...

Related Drug Information
 border=
Abilify
Augmentin
Bactroban Cream
Bactroban Ointment
More...

Related News Articles
 border=
Stimulating Thymus Reactivates T-Cell Production
FDA Panel OKs 3 New Flu Strains for Next Year's Vaccine
Health Tip: Prevent Antibiotic Overuse
2 Mutations Were Critical to Spread of 1918 Flu
More...

THURSDAY, March 1 (HealthDay News) -- A new vaccine may safely protect against hepatitis E, a virus prevalent in developing countries.

In a study of 2,000 healthy adults from Nepal, researchers found that the vaccine was 96 percent effective in preventing hepatitis E infection.

Text Continues Below



"This is the first new hepatitis vaccine strain for which efficacy has been shown since 1992, and it's very well tolerated. I would say this vaccine is a home run," said the study's lead author, Dr. Bruce Innis, vice president of clinical research and development for GlaxoSmithKline, the vaccine's manufacturer.

Results of the study are published in the March 1 issue of the New England Journal of Medicine. The study was funded by GlaxoSmithKline, U.S Army Medical Research and Material Command, and the National Institute of Allergy and Infectious Diseases.

Hepatitis E is an infectious disease that's generally spread through fecal contamination of food or water, according to the World Health Organization (WHO). It's often a self-limiting illness, and most people recover with no long-term consequences. However, women in their third trimester of pregnancy are particularly susceptible to hepatitis E and have a mortality rate as high as 20 percent from the infection.

The hepatitis E virus is relatively uncommon in the United States but is prevalent in other areas of the world. According to background information in the study, it's estimated that as many as one-third of the world's population has been infected with hepatitis E. And, in some countries, such as India, that rate may be as high as 60 percent.

Symptoms of hepatitis E develop from three to eight weeks after exposure, with an average incubation period of 40 days, according to WHO. Those most at risk include people between the ages of 15 and 40, pregnant women and people traveling to countries where hepatitis E is common, according to the U.S. Centers for Disease Control and Prevention. Symptoms of the disease include jaundice, abdominal pain, fatigue, loss of appetite, dark urine, nausea and vomiting.

Page:  1 | 2 | 3 | Next >>

Copyright © 2007 ScoutNews, LLC. All rights reserved.
Last updated 3/1/2007

Related Links
 border=
From Healthscout's partner site on breast cancer, MyBreastCancerNetwork.com
VIDEO: Chemo booster cuts treatment time by two months
SYMPTOMS: Learn what to look for and what the symptoms mean
PROGNOSIS: Early detection and new treatments improve survival rates





New Features

New ADHD Site!

SOURCES: Bruce Innis, M.D., vice president, clinical research and development, GlaxoSmithKline, King of Prussia, Pa.; Tusar Desai, M.D., gastroenterologist and hepatologist, William Beaumont Hospital, Royal Oak, Mich.; March 1, 2007, New England Journal of Medicine


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service   Site Map